Talphera, Inc. TLPH

What this company does

Our portfolio is principally focused on our lead product candidate, Niyad (nafamostat mesylate), for use as a regional anticoagulant during continuous renal replacement therapy, or CRRT. In addition, Talphera may develop LTX-608, a nafamostat formulation for direct IV infusion for one or more of the following indications: disseminated intravascular coagulation, or DIC, acute respiratory distress syndrome, or ARDS, acute pancreatitis, or as an anti-viral treatment. We are developing Niyad to become the first and only FDA-approved regional anticoagulant for use in adult patients undergoing CRRT. Niyad is infused into the extracorporeal circuit, such as the dialysis circuit during CRRT for acute kidney injury, or AKI, patients in the hospital. As of December 31, 2025, Talphera employed 12 full-time employees, most of whom work out of its corporate offices in San Mateo, CA.

Written from the business description in Talphera, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 23 March 2026. Every sentence was checked against that document before publication.